6-fluoro-2-{(7S)-7-methyl-8-[2-(2H-1.2.3-triazol-2-yl)benzoyl]-5.8-diazaspiro[2.6]non-5-yl}quinazoline | 1149352-60-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-fluoro-2-{(7S)-7-methyl-8-[2-(2H-1.2.3-triazol-2-yl)benzoyl]-5.8-diazaspiro[2.6]non-5-yl}quinazoline
• 英文别名: 6-fluoro-2-{(7S)-7-methyl-8-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-5,8-diazaspiro[2.6]non-5-yl}quinazoline；[(7S)-5-(6-fluoroquinazolin-2-yl)-7-methyl-5,8-diazaspiro[2.6]nonan-8-yl]-[2-(triazol-2-yl)phenyl]methanone
• CAS: 1149352-60-2
• 化学式: C₂₅H₂₄FN₇O
• 分子量: 457.51
• InChiKey: GFTPVZTWXKSCTC-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  34
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  80
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-氯-6-氟喹唑啉 、 tert-butyl (7S)-7-methyl-8-[2-(2H-1.2.3-triazol-2-yl)benzoyl]-5.8-diazaspiro[2.6]nonane-5-carboxylate 在 三氟乙酸 、 水 、 sodium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 6-fluoro-2-{(7S)-7-methyl-8-[2-(2H-1.2.3-triazol-2-yl)benzoyl]-5.8-diazaspiro[2.6]non-5-yl}quinazoline
  参考文献：
  名称：

  [EN] SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE, DE TYPE DIAZÉPAN SUBSTITUÉ

  摘要：

  本发明涉及一种二氮平化合物，其为促进睡眠激素受体的拮抗剂，并且在治疗涉及促进睡眠激素受体的神经和精神障碍和疾病方面具有用途。本发明还涉及包括这些化合物的制药组合物以及在治疗涉及促进睡眠激素受体的这些疾病方面使用这些化合物和组合物。

  公开号：

  WO2009058238A1

文献信息

• SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS
  申请人：Bergman Jeffrey M.

  公开号：US20100256121A1

  公开（公告）日：2010-10-07

  The present invention is directed to diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which orexin receptors are involved.

  本发明涉及一种二氮平化合物，其是促进睡眠的药物，可以作为促进睡眠的治疗药物。该化合物是促进睡眠的药物，可以用于治疗神经系统和精神障碍和疾病，这些疾病中涉及到促进睡眠的药物。本发明还涉及包含这些化合物的制药组合物以及在治疗涉及到促进睡眠的疾病时使用这些化合物和组合物的方法。
• Substituted diazepan orexin receptor antagonists
  申请人：Bergman Jeffrey M.

  公开号：US08362009B2

  公开（公告）日：2013-01-29

  The present invention is directed to diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which orexin receptors are involved.

  本发明涉及一种二氮平化合物，其是睡眠肽受体的拮抗剂，可用于治疗涉及睡眠肽受体的神经和精神障碍和疾病。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在治疗涉及睡眠肽受体的疾病中的使用。
• Methods and pharmaceutical compositions for the treatment of cancer
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

  公开号：US10894042B2

  公开（公告）日：2021-01-19

  The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.

  本发明涉及治疗癌症的方法和药物组合物。更具体地说，本发明涉及一种治疗有需要的受试者癌症的方法，该方法包括向受试者施用治疗有效量的至少一种 OX1R 拮抗剂。
• USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
  申请人：Inserm (Institut National De La Sante et de la Recherche Medicale)

  公开号：US20190083508A1

  公开（公告）日：2019-03-21

  The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases.
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCJAE MÉDICALE

  公开号：US20190151304A1

  公开（公告）日：2019-05-23

  The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases. The inventors showed that orexin receptor antagonists have anti-inflammatory properties. Indeed, these compounds are antagonist for OX1R-mediated calcium mobilization but a full agonist for OX1R-mediated mitochondrial apoptosis, which is the mechanism involved in the improvement of resolution of inflammation observed in the models of colitis, multiple sclerosis and pancreatitis. In particular, the present invention relates to a method of treating an autoimmune inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one OX1R antagonist.